Testing an HIV treatment pause to see if cure is possible
Part of Infections clinical trials.
This study looks at whether some people with HIV can keep the virus controlled even if they temporarily stop HIV medicines (an “analytic treatment interruption”). If you qualify, it may help researchers learn what it would take for an HIV cure.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older
- You are living with HIV-1 and your care team thinks you might be a good candidate for possible cure
- On HIV treatment, your blood tests show undetectable virus for at least 6 months on at least two occasions
- During the planned treatment pause, you will avoid sex or use barrier protection (like condoms)
- If you can become pregnant, you can take a pregnancy test and you can use pregnancy prevention methods as required
- You can understand the study and give informed consent
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a combination of powerful antibodies (bNAbs) can help control HIV after stopping standard HIV treatment. Participants will pause their daily HIV medications while receiving these antibodies, and doctors will closely monitor their immune system and virus levels. It's for people who are already well-controlled on HIV treatment and have participated in a specific earlier study.
This Phase 2 study uses special scans (PET/CT) and tissue sampling (biopsy) to learn what is happening in the body while people with HIV take a planned break from antiretroviral therapy (ART) for up to 90 days. It may help researchers find better ways to control HIV without ongoing treatment, though joining involves careful monitoring during the pause.
This study looks at what happens when HIV treatment (ART) is intentionally paused in people who are already enrolled in a specific research study (RV254) and recently joined a protocol that included an earlier treatment pause. It may help researchers understand safety and how to manage treatment changes, but it has strict participation and consent requirements.
This study tests whether a combination approach, including a drug called nicotinamide (a form of vitamin B3) and other strategies, can reduce the hidden HIV reservoir enough to allow a temporary pause in antiretroviral therapy without the virus rebounding. It is for people who have well-controlled HIV and strong immune systems.
This study compares how active the immune system is and how large the “hidden” HIV reservoir is in people on two different HIV treatment types. It may help researchers understand whether staying on a tenofovir-containing regimen leads to better control of HIV hiding in the body.
This international study looks at blood samples from people with HIV to find markers that predict whether someone can control the virus without medication. It involves four groups: natural controllers, people who controlled virus after stopping treatment in a study, non-controllers (whose virus returns), and people stable on ART.
Hear when a new HIV trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.